NewsHealthcare Global Enterprises Reports 13% Revenue Growth in Q3FY26 with Strong Margin ExpansionHealthcare Global Enterprises Reports 13% Revenue Growth in Q3FY26 with Strong Margin Expansion
Healthcare Global Enterprises Limited reported strong Q3FY26 results with consolidated revenue of ₹6,331 Mn, up 13% year-on-year, and adjusted EBITDA of ₹1,108 Mn, representing 20% growth with margin expansion of 98 basis points to 17.5%. For nine months FY26, revenue grew 16% to ₹18,931 Mn with adjusted EBITDA rising 20% to ₹3,458 Mn and margins improving 60 basis points to 18.3%. The company's performance was driven by resilient demand across oncology modalities and operating leverage from its integrated care model.
*this image is generated using AI for illustrative purposes only.
Healthcare Global Enterprises Limited, India's largest dedicated cancer hospital network, announced its financial results for the quarter and nine months ended December 31, 2025. The company demonstrated steady performance with revenue growth and margin expansion despite seasonal challenges in the healthcare industry.
Financial Performance Overview
The company's consolidated financial results showed robust growth across key metrics for both the quarter and nine-month periods:
| Particulars (Rs. Mn.) | Q3FY26 | Q3FY25 | YoY | 9MFY26 | 9MFY25 | YoY |
|---|---|---|---|---|---|---|
| Revenue from Operations | 6,331 | 5,586 | 13% | 18,931 | 16,377 | 16% |
| Adjusted EBITDA | 1,108 | 923 | 20% | 3,458 | 2,893 | 20% |
| Margin (%) | 17.5% | 16.5% | +98 bps | 18.3% | 17.7% | +60 bps |
| Adjusted PAT (Post IND AS) | 6 | 70 | - | 216 | 371 | - |
Management Commentary on Results
Dr. Manish Mattoo, CEO of Healthcare Global Enterprises Ltd., highlighted that the Q3 performance reflects steady execution across the network despite seasonal softness in the healthcare industry. He noted that revenues of ₹6,331 Mn were supported by balanced performance across regional clusters, demonstrating resilient demand for high-quality oncology care across medical, radiation, and surgical oncology modalities.
The quarter demonstrated the scalability of the company's model, with adjusted EBITDA margins expanding due to operating leverage. Dr. Mattoo emphasized that HCG's focused single-specialty model, anchored in integrated care delivery and tumour-board-led clinical decision-making, continues to differentiate the company in a competitive environment, supporting strong referral flows and patient trust.
Strategic Focus and Clinical Excellence
Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, outlined the company's guiding principle of delivering the right treatment the first time with a focus on patient outcomes. As a single-specialty oncology institution with a nationwide network, HCG has built a deeply integrated care model that combines:
- Advanced diagnostics and genomics
- Multi-omics and organ-specific pathology
- Tumour-board-led decision-making
- Emerging therapies such as CAR-T
The company's commitment to clinical research is reflected in HCG clinicians contributing to one of the largest bodies of oncology research from India, with regular representation at leading international forums worldwide.
Organizational Strengthening
The company has completed senior leadership augmentation across key functions including marketing, domestic sales, and international business to support the next phase of growth. This strengthening of leadership bandwidth positions HCG for continued expansion across both metro and non-metro markets in India.
About Healthcare Global Enterprises
Headquartered in Bengaluru, Healthcare Global Enterprises Ltd. operates India's largest dedicated cancer hospital network. Through its network of 25 hospitals across India and Africa, HCG provides advanced cancer care with comprehensive cancer centers offering expertise and technologies for effective diagnosis and treatment under one roof. The company also operates fertility centers under the "Milann" brand.
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
